CDH2 and meningioma: To test the generalizability of pharmacologic inhibition of CDH-2 to block the growth of meningioma cells, we treated primary meningioma cells derived from tumors not included in our cohort of spatially distinct meningioma samples with ADH-1, followed by immunofluorescence for Ki-67 from 2D monocultures (Fig. 6h), and quantification of meningioma tumorigenesis from 3D cocultures with human cerebral organoids (Fig. 6i).